title: Safety, efficacy, and tolerability of differential treatment to prevent and treat vaginal dryness and vulvovaginitis in diabetic women.
abstract: BACKGROUND
  Problems affecting the vaginal tract in diabetic women are very often neglected. The efficacy and safety of three gynecological treatments in diabetic women have been assessed.
  
  
  METHODS
  A single-blind randomized progressive trial on 48 diabetic women affected by vaginal dryness, dyspareunia, and recurrent Candida infections was carried out. The ICIQ Vaginal Symptoms (ICIQ-VS) questionnaire was administered.
  
  
  RESULTS
  The analysis of the parameters of ICIQ-VS questionnaire among the three groups showed significant difference only for "dragging pain" (p = 0.0 19) and "soreness" (p = 0.028). In all groups and for all parameters of the questionnaire, improvement of symptoms was observed. In particular, in Group 1 for all symptoms a highly significant difference was observed, to support the already known benefits of the products and of the proposed combination. Significant improvement was also observed in Group 2.
  
  
  CONCLUSIONS
  The proposed treatment with DermoXEN® Ultracalming Special for diabetics and DermoXEN® Vitexyl vaginal gel exert effective moisturizing and soothing action. Indeed, the aforementioned products have been proven effective for the main gynecological problems of diabetic women.
authors.forename: D
authors.initials: D
authors.lastname: Carati
authors.forename: A
authors.initials: A
authors.lastname: Zizza
authors.forename: M
authors.initials: M
authors.lastname: Guido
authors.forename: A
authors.initials: A
authors.lastname: De Donno
authors.forename: R
authors.initials: R
authors.lastname: Stefanizzi
authors.forename: R
authors.initials: R
authors.lastname: Serra
authors.forename: I
authors.initials: I
authors.lastname: Romano
authors.forename: C
authors.initials: C
authors.lastname: Ouedraogo
authors.forename: M
authors.initials: M
authors.lastname: Megha
authors.forename: A
authors.initials: A
authors.lastname: Tinelli
mesh_terms: D000282:Administration, Intravaginal; D000328:Adult; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy / Q000517:prevention & control*; D048909:Diabetes Complications / Q000188:drug therapy / Q000517:prevention & control*; D003920:Diabetes Mellitus; D004338:Drug Combinations; D004414:Dyspareunia / Q000188:drug therapy / Q000517:prevention & control*; D005260:Female; D005990:Glycerol / Q000627:therapeutic use*; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use*; D019344:Lactic Acid / Q000627:therapeutic use*; D008055:Lipids / Q000627:therapeutic use; D008875:Middle Aged; D010205:Pantothenic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012008:Recurrence; D016037:Single-Blind Method; D014622:Vaginal Creams, Foams, and Jellies / Q000627:therapeutic use; D055675:Viscosupplements / Q000627:therapeutic use*; D014848:Vulvovaginitis / Q000188:drug therapy / Q000517:prevention & control; D062367:ortho-Aminobenzoates / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D008055:Lipids; C085472:Replens; D014622:Vaginal Creams, Foams, and Jellies; D055675:Viscosupplements; D062367:ortho-Aminobenzoates; D010205:Pantothenic Acid; C007288:dexpanthenol; C532345:dihydroavenanthramide D; D019344:Lactic Acid; D006820:Hyaluronic Acid; D005990:Glycerol